|
Daiichi Levofloxacin Patent Upheld in UK Where Sanofi Benefits
The UK Supreme Court’s decision to let stand a lower court’s ruling that Daiichi Sankyo’s supplementary protection certificate (SPC)
for the broad-spectrum antibacterial levofloxacin is valid means Sanofi-Aventis can continue to market the agent in the UK without competition.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives